Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score.

ABSTRACT:

Aims

Deciding to stop or continue anticoagulation for venous thromboembolism (VTE) after initial treatment is challenging, as individual risks of recurrence and bleeding are heterogeneous. The present study aimed to develop and externally validate models for predicting 5-year risks of recurrence and bleeding in patients with VTE without cancer who completed at least 3 months of initial treatment, which can be used to estimate individual absolute benefits and harms of extended anticoagulation.

Methods and results

Competing risk-adjusted models were derived to predict recurrent VTE and clinically relevant bleeding (non-major and major) using 14 readily available patient characteristics. The models were derived from combined individual patient data from the Bleeding Risk Study,

SUBMITTER: de Winter MA 

PROVIDER: S-EPMC10079391 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature